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Worldwide, about 7.6 million people die from cancer every year.
1 Many common cancer types are still untreatable in an advanced stage, or therapy is accompanied by serious side effects and resistance phenomena. The most prominent metalbased antitumor compound, cisplatin (Figure 1 ), shows curative activity in testicular cancer and significant prolongation of life span in ovarian cancer and to a lesser extent in other tumors. 2, 3 In recent years, ruthenium complexes have attracted interest because they exert their tumor-inhibiting effects by a mode of action different from that of Pt compounds. 4 Furthermore, they show a favorable toxicity profile in clinical trials: In the case of the ruthenium-indazole complex KP1019 (Figure 1 ) only very moderate toxicities were observed in a dose range in which proteins were on average loaded with one ruthenium species, which should be sufficient for therapeutic activity. [5] [6] [7] In the case of the Ru(imidazole)(dimethylsulfoxide) complex NAMI-A ( Figure 1 ) the formation of painful blisters was determined as dose-limiting toxicity. 8 Binding to plasma proteins as well as reduction of Ru III to Ru II , resulting in an activation of the metal center, is regarded as an important step in the mode of action of KP1019. 9 The established Pt anticancer drugs are known to damage DNA, but it is not regarded as the main target of NAMI-A and KP1019. 8 Furthermore, the use of multinuclear Pt complexes as chemotherapeutic agents was considered. The trinuclear compound BBR3464 (Figure 1) shown to exhibit no in Vitro activity up to a concentration of 50 µM in A549 and A2780 cancer cells, and coordination to 9-ethylguanine as a DNA model was established. 25 The dinuclear Ru-arene complexes 4a-c were obtained by reaction between the bis[dichlorido(η 6 -p-isopropyltoluene)ruthenium(II)] 3 and deprotonated bis(3-hydroxy-2-methyl-4-pyridinon-1-yl)alkanes 2a-c (alkane ) propane 2a, hexane 2b, dodecane 2c) with yields of 75%, 67%, and 45%, respectively (Scheme 1). The ligands were prepared by a modified method of Hider et al., 26 starting from the naturally available synthone maltol. The benzyl-protected maltol moiety was condensated with primary aliphatic diamines with varying chain lengths of three, six, and 12 CH 2 groups, and the products were isolated as HCl-free compounds (in contrast to previous reports 26 ) by slow crystallization from the reaction mixture or by column chromatography on silica gel. Finally, ligands 2a-c were obtained by catalytic hydrogenolysis of the benzyl group.
The complexes were characterized spectroscopically by 1 H and 13 C NMR and electrospray ionization (ESI) mass spectrometry. The results corroborate the expected structure: Coordination of the metal center to the ligand resulted in an upfield shift of approximately 0.2 ppm for the N-CH proton (at about 7.4 ppm). In ESI mass spectra in both water and methanol, the most abundant peaks were assigned to the doubly charged [M -2Cl] 2+ ions.
Furthermore, [M -Cl]
+ and [M + Na] + ions were detected, containing the highly characteristic isotope pattern for ruthenium and Ru-Cl species, respectively. The molecular structure of 4b · CHCl 3 was determined by X-ray diffraction analysis (Figure 2) . The metal centers adopt the pseudooctahedral "piano-stool" geometry, with the π-bound arene being the seat and the σ-bound chlorido and O,O-chelate occupying the chair's legs. The Ru-C bond lengths are similar to those reported for chlorido[3-(oxo-κO)-2-methyl-4-pyridinonato-κO4](η 6 -p-isopropyltoluene)ruthenium(II) (5), 25 while the Ru-O and the Ru-Cl bonds are slightly contracted in 4b (Table 1) .
The complexes have two stereogenic ruthenium centers, leading to a mixture of diastereoisomers. Due to the presence of an axis of symmetry in the molecules, only one set of signals is observable in the 1 H NMR spectra. In order to study the epimerization of the dinuclear complexes, 1 H NMR measurements were performed for 4b in polar and nonpolar solvents at room temperature (Figure 3 ). In the polar solvents D 2 O and CD 3 OD, the epimerization takes place very quickly, and thus only two doublets were detected for the aromatic protons of the arene group and a single signal for the isopropyl groups as well as a well-defined triplet for the CH 2 -N group (Figures 3a and 3b ). These observations may be due to a fast inversion of the metal center. 27 In contrast, spectra in CDCl 3 show four doublets for the aromatic protons of the arene group and two signals for the isopropyl groups as well as two broad multiplets for the CH 2 -N groups (Figure 3c ). This is in accordance with previously reported results for similar mononuclear complexes. The 50% inhibitory concentrations (IC 50 ) of the new complexes 4a-c have been determined in human ovarian carcinoma (A2780) and colon adenocarcinoma (SW480) cells. IC 50 values decrease in the cell line SW480 from 62 to 26 and 0.29 µM with increasing chain length of the spacer from three to six and 12 CH 2 groups (Table 2, Figure 4) . In A2780 cells, 4a and 4b show similar activity, but again 4c is the most potent compound. 4c is 1 order of magnitude more active than cisplatin and equally active as oxaliplatin in the cell line SW480 and, compared with data from the literature, 28 only 4-5 times less cytotoxic than cisplatin (IC 50 ) 0.33 µM) and oxaliplatin (IC 50 ) 0.40 µM) in the platinumsensitive cell line A2780. Furthermore, 4c is 170 times more cytotoxic in SW480 cells than the mononuclear Ru(III) complex KP1019, which is currently being studied in clinical trials. Although methodological differences have to be considered, 4c is 2 orders of magnitude less cytotoxic than the trinuclear platinum complex BBR3464 (A2780: IC 50 ) 0.01 µM). 29 However, coupling three Pt centers in BBR3464 increases the cytotoxicity only by a factor of approximately 30, whereas the Ru complexes presented here are active only when two metals centers are coupled; that is, the mononuclear analogue is not cytotoxic.
The spacer-length-dependent cytotoxicity in cancer cells implicates a correlation with the lipophilicity of the compounds, which is an important factor for anticancer drugs, since hydrophobic compounds can cross cell membranes easier than hydrophilic ones. 30 The lipophilic character of 4a-c was investigated by determination of the n-octanol/water partition coefficient, log P, applying the shake flask method. 31 Ruthenium contents in the aqueous and octanol phases were quantified by ICP-MS and UV/ vis, respectively, and both methods lead to essentially identical results. Log P values in the range from -1.33 to -0.56 were obtained for the dinuclear compounds and correlate with the length of the spacer linking the pyridinone moieties. The solubility of the dinuclear compounds in water reflects the n-octanol/water partition coefficients. With increasing chain length of the complexes from three to six and 12 CH 2 groups, the solubility in water decreases from about 13.4 to 3.4 and 0.5 mM, respectively, also correlating with the in Vitro activity.
Summarizing, coupling more than one metal center with the aim of improving the anticancer activity of Ru(II)-arene metallodrugs led to the development of complexes with high activity in human tumor cell lines. Notably, not only an additive effect of the analogous mononuclear complexes but a synergistic effect in two cell lines was observed, being of extraordinary dimension in SW480 cells for Ru compounds. For the series of dinuclear compounds, a spacer-length-dependent order of in Vitro activity was found, allowing modulation of both anticancer activity and lipophilicity. However, the mode of action is not absolutely clear yet, and several targets, including DNA but also proteins, are conceivable. Communications Organometallics, Vol. 27, No. 11, 2008 2407 
